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To elucidate the mechanism of anemia and leukopenia in the patients with liver cirrhosis, we investigated hematopoietic progenitor cell contents in their bone marrow, and the effects of their sera and blood mononuclear cells on hematopoietic progenitors from normal subjects. While there was no significant difference in the number of marrow CFU-E and BFU-E between the patients with liver cirrhosis and normal subjects, the number of marrow CFU-C was significantly reduced in liver cirrhosis patients. Patients' sera suppressed in vitro colony formation of normal CFU-E, BFU-E, and CFU-C, and the degree of suppression was well correlated with severity of anemia or granulocytopenia.
In vitro colony formation of normal hematopoietic progenitor cells was not affected by blood mononuclear cells from liver cirrhosis patients.
These results indicate that the appearance of humoral inhibitor(s) of hematopoietic progenitors plays a role in the development of anemia and granulocytopenia in liver cirrhosis.
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Anemia and leukopenia are frequent manifestations of chronic liver diseases, particularly, liver cirrhosis1' 2\ Approximately 40 to 70% of the patients with liver cirrhosis are found to have anemia1'3^.
It can be caused by acute and/or chronic bleeding from the upper gastrointestinal tract and hemorrhoid, but it is often observed despite of no obvious bleeding. As the developing mechanism of anemia in such patients, folate deficiency4^, hypersplenism5) and hemolysis such as spur cell anemia6^have been described. Granulocytopenia in liver cirrhosis has been ascribed to increase of marginal granulocytic pool and appearance of splenic inhibitory factor of granulopoiesis7\
We investigated hematopoietic progenitor cell contents in the bone marrow of the patients with liver cirrhosis, and the effects of their sera and blood mononuclear cells on hematopoietic progenitors from normal subjects to elucidate the mechanism of anemia and granulocytopenia in this disorder. 
MATERIALS

Culture ofHematopoietic Progenitors
In vitro CFU-E (erythroid colony-forming units) and BFU-E (burst-forming units-erythroid) assays were performed using the plasma clot method of Terasawa et al.8^with minor modifications.
In brief, 8xlO4 bone marrow mononuclear cells were inoculated in a culture plate (Falcon, U.S.A.) with 1.0 u/ml (for CFU-E) and 2.0 u/ml (for BFU-E) of erythropoietin (Connaught,
Step III, U.S.A.). After seven days (for CFU-E) and 14 days (for BFU-E) incubation at 37°C in fully humidified atmosphere with 5% carbon dioxide in air, the plasma clot was fixed with 5% glutaraldehyde and stained with benzidine. Cell aggregates consisting of 8 or more benzidine-positive cells were scored as CFU-E derived colonies and those consisting of 50 or more benzidine-positive cells, and three or more cluster aggregates, each containing 8 to 49 benzidine-positive cells, were scored as BFU-E derived colonies. For CFU-C (granulocyte-macrophage colony forming unit) assay, the monolayer soft agar method by Bradley and Metcalf9^ was used with minor modifications. In brief, 2xlO5 bone marrow mononuclear cells were suspended in 1 ml of culture medium containing 0.3% bacto-agar in a 35mm Falcon petri dish. The leukocyteconditioned medium prepared from normal human peripheral leukocytes10\ as a source of colony stimulating factor, was added to the culture system at a final concentration of 20%. Duplicate cultures were incubated for 12 days at 37°C in fully humidified atmosphere with 5% carbon dioxide in air. Aggregates consisting of 50 or more cells were scored as CFU-C colonies.
Statistical Analysis
The Student's t-test was used to determine statistically RESULTS
Hematopoietic Progenitor Contents in the Bone
Marro w The numbers of CFU-E derived colonies were 180.4 ± 119.2 in the whole patients (mean ± SD, n=15), 173.7 ± 96.5 (n=7)in anemic group, 180.6 ± 153.0 (n=8) in non-anemic group, and 157.2 ± 73.4 (n=10) in control group. There was no significant difference in these four groups. Similarly, BFU-E derived colonies in the four groups were 38.8 ± 26.8 (n=10), 38.6 ± 14.3 (n=5), 39.0 ± 37.5 (n=5), 49.1 ± 35.2 (n=7), respectively and there also was no significant difference in these four groups. By contrast, the number of CFU-C derived colonies were 77.3 ± 46.9 (n=14) in the whole patients and 125.5 ± 45.7 (n=10) in control group. These values were significantly different one from the other (p < 0.04). Further, CFU-C colony counts were 39.0 ± 18.7 (n=5) in granulocytopenic group and 98.6 ± 44.4 (n=9) in non-granulocytopenic group (P < 0.02) (Fig. 1 f not significant *The results were expressed as a percentage of the colony count without addition of mononuclear cells.
Patients' peripheral mononuclear cells were added to marrow hematopoietic progenitor culture system of ABO-compatible normal subjects at ratio 1:1. Addition of patients' peripheral blood mononuclear cells did not influence the colony formations of normalCFU-E, BFU-E, or CFU-C ( of CFU-E and BFU-E themselves. We also found that the sera of liver cirrhosis patients with granulocytopenia suppressed in vitro colony formation of normal marrow CFU-C, and that the degree of suppression was well correlated with the severity of granulocytopenia. The appearance of this inhibitor may be one of the causes of granulocytopenia in liver cirrhosis. It is not obvious whether or not the serum inhibitory factor found in our study is identical with so-called splenic inhibitor.
This CFU-C inhibitory factor may be different from our erythroid inhibitor, since marrow CFU-C significantly decreased in the liver cirrhosis patients where CFU-E and BFU-E remained normal in number. It is speculated that the CFU-C inhibitory factor suppresses proliferation of granulocyto- 
